---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178954"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:39:28.692969+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica Q2 net income $0.2M; YCANTH units +32.8% QoQ; Nasdaq compliance regained

## Summary
- Q2 product revenue $4.5M; license & collaboration revenue $8.2M (incl. $8.0M Torii milestone). Net income $0.2M ($0.02 GAAP EPS) vs net loss $17.2M YoY.
- YCANTH dispensed applicator units 13,434, sequential growth of 32.8% over Q1'25. Revenue net $4.5M up 32.5% sequentially.
- Regained Nasdaq bid price compliance after 1-for-10 reverse stock split on July 24, 2025.
- Torii accelerated $8M milestone payment received July 2025; additional $10M milestone upon Japanese YCANTH approval expected by end of 2025.
- Completed End-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); preparing Phase 3 program and exploring non-dilutive funding.

## SEC filing metadata
- accession: 0001193125-25-178954
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/0001193125-25-178954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/d409147d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178954
- JSON: https://secwatch.observer/filing/0001193125-25-178954.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.